medigraphic.com
ISSN 1729-519X (Print)

2021, Number 3

<< Back Next >>

Revista Habanera de Ciencias Médicas 2021; 20 (3)

Peutz-Jeghers syndrome, telangiectasias, and mitral valve prolapse. Case presentation and genetic counseling

Arús FAE, Arús SE

Language: Spanish
References: 22
Page: 1-7
PDF size: 721.04 Kb.


ABSTRACT

Introduction: Peutz-Jeghers syndrome is characterized by mucocutaneous hyperpigmentation and gastrointestinal hamartomas that can appear from the stomach to the anus. It has an autosomal dominant inheritance pattern and variable expressiveness. The diagnosis is based on clinical findings and histological appearance of the polyps. No association between this entity and telangiectasias and mitral valve prolapse has been reported so far.
Objective: To describe the findings that made it possible to establish the diagnosis of Peutz-Jeghers syndrome in a patient and to provide genetic counseling.
Case presentation: Thirty-six-year-old male patient with a history of mitral valve prolapse who attends a clinical genetics consultation with his wife to request genetic counseling due to the fact that their daughter was diagnosed with Peutz-Jeghers Syndrome and they want to know about the risk of having another affected child. On physical examination, a hyperpigmented macule on the lower lip and several of these on the gums were observed. With such findings and the antecedent of having a daughter with Peutz-Jeghers syndrome, the same diagnosis is made in the father. As data of interest, multiple telangiectasias on the thorax, neck and back were found in this individual. The studies carried out to identify the same cause were negative.
Conclusions: The history and findings in this patient allowed us to make the diagnosis of Peutz-Jeghers syndrome as well as to provide genetic counselling. The first report of this disease associated with telangiectasias and mitral valve prolapse is presented in the scientific literature.


REFERENCES

  1. Jelsig AM, Qvist N, Brusgaard K, Nielsen CB, Hansen TP, Ousager LB. Hamartomatous polyposis syndromes: A review. Orphanet J Raro Dis [Internet]. 2014 [Citado 18/09/2020];9(101):[Aprox. 2 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112971/

  2. Rodríguez FA, Sorlí JV, Romero IM, Codoñer P. Registro y seguimiento clínico de pacientes con síndrome de Peutz Jeghers en Valencia. Rev Gastroenterol (Méx). 2020; 85(2): 123-39.

  3. McGarrity TJ, Amos CI, Baker MJ. Peutz-Jeghers Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, et al, eds. GeneReviews(r) [Internet]. Seattle (WA): University of Washington; 2021. [Citado 18/09/2020]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20301443/

  4. Latchford A, Cohen S, Auth M, Scaillon M, Viala J, Daniels R, et al. Management of Peutz-Jeghers Syndrome in Children and Adolescents: A Position Paper From the ESPGHAN Polyposis Working Group. J Pediatr Gastroenterol Nutr. 2019; 68(3): 442-52.

  5. Meserve E, Nucci M. Peutz-Jeghers Syndrome Pathobiology, Pathologic Manifestations, and Suggestions for Recommending Genetic Testing in Pathology Reports. Surg Pathol Clin. 2016; 9:243-68.

  6. Monica M, Auerkari E. Molecular Genetics of Peutz-Jegher Syndrome. Adv Heal Sci Res. 2018; 4:142-59.

  7. Chen HM, Fang JY. Genetics of the hamartomatous poly-posis syndromes: A molecular review. Int J Colorectal Dis. 2009; 24:865-74.

  8. Achatz MI, Porter C, Brugieres L, Druker H, Frebourg T, Foulkes WD, et al. Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. Clin Cancer Res. 2017; 23(13): e107-e14.

  9. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. Am J Gastroenterol. 2015; 110:223-62.

  10. Orso PR, Tadeu B, Machado LE, Tokarski M. A Case of benign hereditary telangiectasia without family history. An Bras Dermatol. 2017; 92 (1):162-3.

  11. Schieving JH, Schoenaker MHD, Weemaes CM, van Deuren M, van der Flier M, Seyger MM, et al. Telangiectasias: small lesions referring to serious disorders. Eur J Paediatr Neurol. 2017; 21 (6):807-15.

  12. McDonald J, Pyeritz RE. Hereditary Hemorrhagic Telangiectasia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, et al, eds. GeneReviews(r) [Internet]. Seattle (WA): University of Washington; 2021. [Citado 18/09/2020]. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/20301525/

  13. Andrabi S, Bekheirnia MR, Robbins Furman P, Lewis RA, Prior TW, Potocki L. SMAD4mutation segregating in a family with juvenile polyposis, aortopathy, and mitral valve dysfunction. 2011. Am J Med Genet. 2011; 155: 1165-69.

  14. Benítez J, Núria Malats A, Osorio A, Robledo M, Rodríguez S. Glosario de Genética-Probando o caso índice [Internet]. España: Fundación Instituto Roche; 2020 [Citado 18/09/2020]. Disponible en: https://www.institutoroche.es/recursos/glosario/probando

  15. Stratakis CA, Raygada M. Carney Complex. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, et al, eds. GeneReviews(r) [Internet]. Seattle (WA): University of Washington; 2021. [Citado 18/09/2020]. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/20301463/

  16. Carcavilla A, Santomé J, Pinto I, Sánchez Pozo J, Guillén Navaro E, Martín Frías M, et al. Síndrome LEOPARD: una variante del síndrome de Noonan con fuerte asociación a miocardiopatía hipertrófica. Rev Esp Cardiol. 2013; 66(5):350-56.

  17. Goldman M, Bennett RG. Treatment of telangiectasia: A review. J Am Acad Dermatol. 1987; 17(2):167-82.

  18. Payne SC, Feldstein D, Anne S, Tunkel DE. Hypertension and Epistaxis: Why Is There Limited Guidance in the Nosebleed Clinical Practice Guidelines. Otolaryngol Head Neck Surg. 2020; 162(1):33-4.

  19. Haidle JL, Howe JR. Juvenile Polyposis Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, et al, eds. GeneReviews(r) [Internet]. Seattle (WA): University of Washington; 2021. [Citado 18/09/2020]. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/20301642/

  20. Sweet K, Willis J, Zhou XP, Gallione C, Sawada T, Alhopuro P, et al. Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis. JAMA. 2005; 294(19):2465-73.

  21. Hui L, Nianshuang L, Huan H, Ying Y, Shashank S, Lingyu L, et al. AMPK Inhibits the Stimulatory Effects of TGF-ß on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition. Mol Pharmacol. 2015; 88(6):1062-71.

  22. Nian Shuang L, Jun Rong Z, Hui L, Rong K, Xiao Ling H, Lu X, et al. LKB1/AMPK inhibits TGF-ß1 production and the TGF-ß signaling pathway in breast cancer cells. Tumour Biol. 2016; 37(6):8249-58.




2020     |     www.medigraphic.com